CRISPR-Cas gene editing methods is an emerging powerful tools in biosciences. Applications of CRISPR to synthetics biology, biotechnology, personalized medicine, drug discovery etc, generates a series of legal and bioethics questions. This generates in turn the necessity of new regulatory issues. In this work we discuss more recent applications of CRIPSR focused on drug discovery with incidence of human genome information. This includes, but is not limited to: resistance-selection studies of antimalarial drugs; new animal models for drug assay, etc. We also, discuss the legal regulation and ethical aspects of this area of human genome editing related to drug discovery.
Previous Article in event
Next Article in event
CRISPR-Cas Gene Editing: Regulatory Issues and Applications
Published: 25 November 2017 by MDPI in MOL2NET'16, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 2nd ed. congress USEDAT-02: USA-Europe Data Analysis Training Program Workshop, Cambridge, UK-Bilbao, Spain-Miami, USA, 2016
Keywords: CRISPR-Cas; Drug discovery; Human genome; Gene editing legal issues